 | Up a level |
Stratmann, J. A., Hornetz, S., Griesinger, F., Wolf, J., Christoph, D. C., Sackmann, S., Spengler, W., Bischoff, H., Schaefer, M., Alt, J., Mlueller, A., Laack, E., Kimmich, M. and Sebastian, M. (2017). An expanded access program of osimertinib (Tagrisso) in patients with advanced non-small cell lung cancer: data report from Germany. Oncol. Res. Treat., 40. S. 170 - 171. BASEL: KARGER. ISSN 2296-5262
Walter, R. F. H., Mairinger, F. D., Ting, S., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W. and Wohlschlaeger, J. (2015). MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br. J. Cancer, 112 (5). S. 883 - 891. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827
Walter, R. F. H., Mairinger, F. D., Ting, S., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W. and Wohlschlaeger, J. (2015). MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br. J. Cancer, 112 (5). S. 883 - 891. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827